赋能精准再生修复的工程化外泌体构建的研究进展
吴潘 ,马莹 ,安桐 ,黎达琴 ,王润轩 ,宋会娟 ,何宁宁 *,刘强 *
作者信息
- 中国医学科学院 & 北京协和医学院放射医学研究所,天津 300192
*通信作者
摘要
外泌体作为细胞间通讯的关键介质,已成为无细胞疗法领域极具前景的候选者。与传统干细胞疗法相比,外泌体疗法具有免疫原性低和有效跨越生物屏障的优势。 然而,天然外泌体在发挥疗效时易受到其快速清除、靶向能力有限以及载荷不足的阻碍。为了克服这些瓶颈,该领域已实现了从使用天然外泌体向开发下一代工程化外泌体的范式转变。 全面总结近 5 年(2021 至 2026 年)在外泌体工程化策略方面的进展,主要围绕膜蛋白修饰与内容物装载两大策略;详细探讨了膜支架蛋白的发展历程,对比评估了外源性装载策略(如电穿孔、皂苷透化)与基于基因工程介导的内源性装载系统;重点阐述了这些工程化外泌体在特定疾病中的治疗效能;前瞻性地展望了人工智能(如 AlphaFold2 和 RFdiffusion)在支架蛋白理性设计和微型结合蛋白从头设计方面的可能性。 下一代外泌体有望突破现有技术瓶颈,发展为用于精准损伤修复和基因治疗的智能纳米药物。
Research advances on the construction of engineered exosomes for precision regenerative repair
Pan WU , Ying MA , Tong AN , Daqin LI , Runxuan WANG , Huijuan, SONG , Ningning HE *, Qiang LIU *
Author Information
- Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
*Corresponding author
Abstract
Exosomes, as key mediators of intercellular communication, have emerged as highly promising candidates in the field of cell-free therapy. Compared to traditional stem cell therapies, exosome therapy offers the advantages of low immunogenicity and the ability to effectively cross biological barriers. However, the therapeutic efficacy of natural exosomes is often hindered by their rapid clearance, limited targeting capabilities, and insufficient cargo capacity. To overcome these bottlenecks, the field has undergone a paradigm shift from the use of natural exosomes to the development of next-generation engineered exosomes. This review comprehensively summarizes the advances in exosome engineering strategies over the past five years (from 2021 to 2026), focusing primarily on two major approaches: membrane protein modification and cargo loading. The article discusses in detail the developmental history of membrane scaffold proteins, while also comparatively evaluating exogenous loading strategies (such as electroporation and saponin permeabilization) and genetic engineering-mediated endogenous loading systems. Furthermore, this paper highlights the therapeutic efficacy of these engineered exosomes in specific diseases. Finally, this review provides a forward-looking perspective on the potential of artificial intelligence ( such as AlphaFold2 and RFdiffusion) in the rational design of scaffold proteins and the de novo design of mini-binders. Next-generation exosomes are expected to break through existing technological bottlenecks and evolve into smart nanomedicines for precise injury repair and gene therapy.
Keywords
利益冲突:作者均声明无利益冲突
